Get started
Author

Tilak Mendis

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease
2016 · Huntington Study Group, Samuel Frank, et al. · JAMA · 405
PDF
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
2008 · M. Stacy, D. Silver, et al. · Neurology · 182
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
2018 · Ralf Reilmann, Andrew McGarry, et al. · The Lancet Neurology · 111
Clinical Effects of Choline in Alzheimer's Disease
1978 · P. Etienne, S. Gauthier, et al. · The Lancet · 106
Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
2000 · Erich Mohr, Tilak Mendis, et al. · Movement Disorders · 86
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease A Randomized Clinical Trial
2016 · Samuel Frank, Claudia Testa, et al. · Publisher · 45
Utility of Clinical Trial Batteries in the Measurement of Alzheimer’s and Huntington’s Dementia
1996 · Erich Mohr, Denise Walker, et al. · International Psychogeriatrics · 40
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
2024 · Ralf Reilmann, Karen E Anderson, et al. · The Lancet Neurology · 35
PDF
Late cognitive changes in Parkinson's disease with an emphasis on dementia.
1995 · E Mohr, T Mendis, et al. · PubMed · 35
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
2022 · Samuel Frank, Claudia Testa, et al. · CNS Drugs · 33
PDF
Activity enhances dopaminergic long-duration response in Parkinson disease
2012 · Un Jung Kang, Peggy Auinger, et al. · Neurology · 28
PDF
Impact of standard of care for psychosis in Parkinson disease
2008 · T R Thomsen, M Panisset, et al. · Journal of Neurology Neurosurgery & Psychiatry · 28
Cognitive and Quantified Electroencephalographic Correlates of Cycloserine Treatment in Alzheimerʼs Disease
1995 · Erich Mohr, Verner Knott, et al. · Clinical Neuropharmacology · 28
Management of Parkinson's disease a review of current and new therapies.
1999 · T Mendis, O Suchowersky, et al. · PubMed · 27
Bilateral Facial Paralysis Following Ethylene Glycol Ingestion
1986 · K.B. Mallya, T. Mendis, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 27
PDF
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies
2022 · Olivier Rascol, Lars Tönges, et al. · Parkinsonism & Related Disorders · 22
A profile analysis of demented and nondemented Parkinson's disease patients.
1996 · L McFadden, E Mohr, et al. · PubMed · 19
Effect of Benztropine on Haloperidol-Induced Prolactin Secretion
2008 · S. Lal, T. Mendis, et al. · Neuropsychobiology · 18
Treatment of Alzheimerʼs Disease with Sabeluzole
1997 · Erich Mohr, N. P. Vasavan Nair, et al. · Clinical Neuropharmacology · 17
Neurotransmitter replacement therapy in Alzheimer's disease.
1994 · E Mohr, T Mendis, et al. · PubMed · 16
Worsening of motor function in Parkinson’s disease: A “typical” response to “atypical” antipsychotic medications
2001 · Erich Mohr, K. Hildebrand, et al. · Neurology · 15
Drug-Induced Psychosis in Parkinsonʼs Disease
1996 · Tilak Mendis, C. Lynn Barclay, et al. · CNS Drugs · 14
Symptomatic relief from treatment‐induced psychosis in Parkinson's disease: An open‐label pilot study with remoxipride
1994 · Tilak Mendis, Erich Mohr, et al. · Movement Disorders · 13
EEG and the Passive P300 in Dementia of the Alzheimer Type
1999 · Verner Knott, Erich Mohr, et al. · Clinical Electroencephalography · 11
Symptomatic Relief From Treatment Induced Psychosis in Parkinsonʼs Desease: a Pilot Study With Remoxipride
1992 · E. Mohr, T. Mendis, et al. · Clinical Neuropharmacology · 1
Works count: 29
Citation count: 1,361
H-index: 18
I10-index: 24
Year
Topic
Type